Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (16684)	3/7/1998 7:06:00 AM
From: Henry Niman	Respond to of 32384

The currents Science paper is by the same Memorial Sloan Kettering group that published last week in Nature Genetics, but this article focuses more on the fusion protein. The Science paper on STATs will almost certainly be accompanied by a press release, and I suspect that the press release will come out the night before publication, which is what happened with the Nature paper on Targretin and Type II Diabetes. Last week's Nature Genetics paper was uploaded at: Message 3553171 Here's the abstract of the Science paper from SKI: Role of PML in Cell Growth and the Retinoic Acid Pathway Zhu Gang Wang, * Laurent Delva, * Mirella Gaboli, Roberta Rivi, Marco Giorgio, Carlos Cordon-Cardo, Frank Grosveld, Pier Paolo Pandolfi The PML gene is fused to the retinoic acid receptor (RAR) gene in chromosomal translocations associated with acute promyelocytic leukemia (APL). Ablation of murine PML protein by homologous recombination revealed that PML regulates hemopoietic differentiation and controls cell growth and tumorigenesis. PML function was essential for the tumor-growth-suppressive activity of retinoic acid (RA) and for its ability to induce terminal myeloid differentiation of precursor cells. PML was needed for the RA-dependent transactivation of the p21WAF1/CIP1 gene, which regulates cell cycle progression and cellular differentiation. These results indicate that PML is a critical component of the RA pathway and that disruption of its activity by the PML-RAR fusion protein may be important in APL pathogenesis. Z. G. Wang, L. Delva, M. Gaboli, R. Rivi, M. Giorgio, P. P. Pandolfi, Department of Human Genetics and Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, 1275 York Avenue, New York, NY 10021, USA. C. Cordon-Cardo, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. F. Grosveld, Department of Cell Biology and Genetics, Faculty of Medicine, Erasmus University, Post Office Box 1738, 3000 DR, Rotterdam, Netherlands. * These authors contributed equally to this work. To whom correspondence should be addressed. E-mail: p-pandolfi@ski.mskcc.org

To: Torben Noerup Nielsen who wrote (16684)	3/7/1998 6:54:00 PM
From: tonyt	Respond to of 32384

> So far, the only thing I can figure regarding Monday is a single article > in Science concerning retinoic acid. It's available on-line now, but I haven't > had a chance to really go through it. Looks like you hit the nail on the head about all this 'cloak and dagger' being about the Science Article.